These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

374 related items for PubMed ID: 17268039

  • 1. Bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in drug-eluting stent implantations in the absence of acute myocardial infarction: clinical and economic results.
    Mishkel GJ, Moore AL, Markwell SJ, Ligon RW.
    J Invasive Cardiol; 2007 Feb; 19(2):63-8. PubMed ID: 17268039
    [Abstract] [Full Text] [Related]

  • 2. Bivalirudin and DES: a PCI strategy that pays.
    Applegate RJ.
    J Invasive Cardiol; 2007 Feb; 19(2):69-70. PubMed ID: 17268040
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.
    Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Kereiakes DJ, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ, REPLACE-2 Investigators.
    JAMA; 2003 Feb 19; 289(7):853-63. PubMed ID: 12588269
    [Abstract] [Full Text] [Related]

  • 8. Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial.
    Rajagopal V, Lincoff AM, Cohen DJ, Gurm HS, Hu T, Desmet WJ, Kleiman NS, Bittl JA, Feit F, Topol EJ.
    Am Heart J; 2006 Jul 19; 152(1):149-54. PubMed ID: 16824845
    [Abstract] [Full Text] [Related]

  • 9. Economic evaluation of bivalirudin with or without glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for early invasive management of acute coronary syndromes.
    Pinto DS, Stone GW, Shi C, Dunn ES, Reynolds MR, York M, Walczak J, Berezin RH, Mehran R, McLaurin BT, Cox DA, Ohman EM, Lincoff AM, Cohen DJ, ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) Investigators.
    J Am Coll Cardiol; 2008 Nov 25; 52(22):1758-68. PubMed ID: 19022155
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of bivalirudin in patients with diabetes mellitus undergoing percutaneous coronary intervention in current clinical practice.
    Kim LK, Wong SC, Minutello RM, Bergman G, Feldman DN.
    J Invasive Cardiol; 2010 Mar 25; 22(3):94-100. PubMed ID: 20197573
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness analysis of antithrombotic therapy in nonurgent percutaneous coronary intervention.
    Summers KM, Holdford DA, Crouch MA.
    Pharmacotherapy; 2006 May 25; 26(5):609-18. PubMed ID: 16637790
    [Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of acute ST-segment elevation myocardial infarction.
    Schwenkglenks M, Toward TJ, Plent S, Szucs TD, Blackman DJ, Baumbach A.
    Heart; 2012 Apr 25; 98(7):544-51. PubMed ID: 22313548
    [Abstract] [Full Text] [Related]

  • 16. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial.
    Stone GW, White HD, Ohman EM, Bertrand ME, Lincoff AM, McLaurin BT, Cox DA, Pocock SJ, Ware JH, Feit F, Colombo A, Manoukian SV, Lansky AJ, Mehran R, Moses JW, Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial investigators.
    Lancet; 2007 Mar 17; 369(9565):907-19. PubMed ID: 17368152
    [Abstract] [Full Text] [Related]

  • 17. A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial.
    Moliterno DJ, TENACITY Steering Committee and Investigators.
    Catheter Cardiovasc Interv; 2011 Jun 01; 77(7):1001-9. PubMed ID: 21598351
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Bivalirudin during primary PCI in acute myocardial infarction.
    Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Kirtane AJ, Parise H, Mehran R, HORIZONS-AMI Trial Investigators.
    N Engl J Med; 2008 May 22; 358(21):2218-30. PubMed ID: 18499566
    [Abstract] [Full Text] [Related]

  • 20. Effect of bivalirudin compared with unfractionated heparin plus abciximab on infarct size and myocardial recovery after primary percutaneous coronary intervention: the horizons-AMI CMRI substudy.
    Wöhrle J, Merkle N, Kunze M, Cristea E, Mehran R, Rottbauer W, Stone GW.
    Catheter Cardiovasc Interv; 2012 Jun 01; 79(7):1083-9. PubMed ID: 22162175
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.